Synthetic Biology Understanding of genes, cells, along with advances in AI have caused engineering cells and organisms on a genome-wide sc... Read Article

Political & Constitutional Dimensions: The government, through the Department of Biotechnology (DBT) and the Ministry of Science and Technology, promotes synthetic biology as a strategic sector for economic growth and self-reliance (Atmanirbhar Bharat). India's National Biotechnology Development Strategy (2015-2020) emphasizes innovation and commercialization. Critics, including civil society groups, argue that India lacks a comprehensive regulatory framework for synthetic biology, unlike the Cartagena Protocol on Biosafety which India ratified. The absence of specific legislation raises constitutional questions under Article 21 (right to life) regarding environmental and health safeguards. Opposition parties have raised concerns about biosecurity and the need for parliamentary oversight, especially given the dual-use nature of the technology.

Economic & Financial Impact: Synthetic biology has significant fiscal implications. The global synthetic biology market is projected to grow rapidly, and India aims to capture a share through initiatives like the Biotechnology Industry Research Assistance Council (BIRAC). The article notes that personalized therapies could be particularly expensive, raising equity concerns. Proponents argue that synthetic biology can reduce costs in sectors like pharmaceuticals (e.g., insulin production) and agriculture (e.g., biofortified crops). Critics warn that high costs of R&D and intellectual property rights could concentrate benefits in a few corporations, exacerbating inequality. The government's budgetary allocation for biotechnology (around ₹7,000 crore in 2025-26) supports research but may be insufficient for large-scale commercialization.

Social Dimensions: Synthetic biology offers potential welfare benefits, such as Golden Rice (modified to produce beta-carotene) to address Vitamin A deficiency in developing countries. The article cites this example. However, ethical challenges include equity and distribution of risk, benefits, and access. Critics argue that genetically engineered organisms could harm biodiversity and traditional farming practices, affecting smallholder farmers. The biosafety risk of releasing engineered microorganisms into the environment could disproportionately impact vulnerable communities lacking infrastructure to manage accidents. Public acceptance remains low due to concerns about 'playing God' and unknown long-term effects, as seen in debates over genetically modified (GM) crops in India.

Governance & Administrative Aspects: Implementation challenges include the absence of a dedicated regulatory body for synthetic biology. Currently, the Review Committee on Genetic Manipulation (RCGM) under DBT and the Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment, Forest and Climate Change oversee genetically modified organisms (GMOs), but synthetic biology products may fall outside their scope. The article highlights cyberbiosecurity risks due to growing interaction between biology and automation, requiring coordination between DBT, Ministry of Electronics and IT, and cybersecurity agencies. Federalism implications arise because states have jurisdiction over agriculture and health, leading to potential conflicts (e.g., some states banning GM crops). Institutional capacity for risk assessment and monitoring is limited, especially in rural areas.

International Perspective: Globally, synthetic biology is governed by the Cartagena Protocol on Biosafety (2003), which India ratified. The Biological Weapons Convention (1975) prohibits development of bioweapons, but the article notes that synthetic biology could empower nefarious actors to develop toxins. The US has established the Synthetic Biology Engineering Research Center (SynBERC) and the EU has the Synthetic Biology ERA-Net. India's approach lags behind in terms of regulatory clarity and investment. Diplomatic implications include the need to balance promoting innovation with fulfilling international obligations under the Convention on Biological Diversity (CBD). The COVID-19 pandemic demonstrated the importance of global cooperation in synthetic biology (e.g., mRNA vaccine development), but also raised concerns about equitable access to therapies.